Unknown

Dataset Information

0

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.


ABSTRACT:

Purpose

Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/E-120) linked to fragment antigen binding moiety of a monoclonal antibody recognizing the tumor-associated antigen 5T4.

Patients and methods

Patients with non-small-cell lung cancer (NSCLC), pancreatic cancer (PC), and renal cell cancer (RCC) received 5 daily boluses of ABR-217620 (3-month cycles) in escalating doses to determine the maximum-tolerated dose (MTD; ABR-217620 dose escalation monotherapy [MONO] study). Doses were selected based on individual patient anti-SEA/E-120 titers pretreatment. Patients with NSCLC received 4 daily, escalating doses of ABR-217620 followed by docetaxel in 21-day cycles (ABR-217620 dose escalation combination with docetaxel [COMBO] study).

Results

Thirty-nine patients were enrolled in the MONO study and 13 were enrolled in the COMBO study. The monotherapy MTD was 26 microg/kg (NSCLC and PC) and 15 microg/kg (RCC). Dose-limiting toxicities (DLTs) in the MONO study were fever, hypotension, acute liver toxicity, and vascular leak syndrome. In the COMBO study, the MTD was 22 microg/kg (neutropenic sepsis). Adverse events included grade 1 to 2 fever, hypotension, nausea, and chills. Treatment caused a systemic increase of inflammatory cytokines and selective expansion of SEA/E-120 reactive T-cells. Tumor biopsies demonstrated T-cell infiltration after therapy. Fourteen patients (36%) had stable disease (SD) on day 56 of the MONO study. Two patients (15%) in the COMBO study had partial responses, one in a patient with progressive disease on prior docetaxel, and five patients (38%) had SD on day 56.

Conclusion

ABR-217620 was well tolerated with evidence of immunological activity and antitumor activity.

SUBMITTER: Borghaei H 

PROVIDER: S-EPMC2734423 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.

Borghaei Hossein H   Alpaugh Katherine K   Hedlund Gunnar G   Forsberg Göran G   Langer Corey C   Rogatko Andre A   Hawkins Robert R   Dueland Svein S   Lassen Ulrik U   Cohen Roger B RB  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090727 25


<h4>Purpose</h4>Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/E-120) linked to fragment antigen binding moiety of a monoclonal antibody recognizing the tumor-associated antigen 5T4.<h4>Patients and methods</h4>Patients with non-small-cell lung cancer (NSCLC), pancreatic cancer (PC), and renal cell cancer (RCC) received 5 daily bolus  ...[more]

Similar Datasets

| S-EPMC5036398 | biostudies-literature
| S-EPMC10225203 | biostudies-literature
| S-EPMC2790853 | biostudies-literature
| S-EPMC3419955 | biostudies-literature
| S-EPMC3313020 | biostudies-literature
| S-EPMC9402746 | biostudies-literature
| S-EPMC5340007 | biostudies-literature
| S-EPMC5901648 | biostudies-literature
| S-EPMC4410974 | biostudies-literature
| S-EPMC4228391 | biostudies-literature